Top Markets
#1 Ontology Gas Ontology Gas +23.38%
#2 EXOD EXOD +22.08%
#3 Status Status +20.38%
#4 ETHGas ETHGas +14.18%
#5 aelf aelf +13.27%
#6 Fake World Assets Fake World Assets +10.63%
#7 The Black Bull The Black Bull +10.03%
#8 Derive Derive +8.64%
#9 Gas Gas +7.44%
#10 Meteora Meteora +6.38%
Coin of the day
Ontology Gas Ontology Gas
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Classement en actions #25523
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Prix de l'action
$9.81
Dernière synchronisation: 2025-03-18
Capitalisation boursière
$48.68M
Changement (1 jour)
1.55%
Changement (1 an)
0.00%
Pays
US
Échange AlloVir, Inc. (ALVR)

Catégorie

Healthcare
Revenus pour AlloVir, Inc. (ALVR)
Revenus en Jun 2026 TTM : 0.00
Selon les derniers rapports financiers de AlloVir, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0.00. En 2023, l'entreprise a réalisé un chiffre d'affaires de 0.00 égal à le chiffre d'affaires de l'année 2022, qui était de 0.00. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour AlloVir, Inc. de 2018 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 -100.00%
2019 $165.00K -85.46%
2018 $1.14M 0.00%
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US